D I Abrams

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Vaporization as a smokeless cannabis delivery system: a pilot study
    D I Abrams
    Community Consortium, Positive Health Program, San Francisco General Hospital, San Francisco, California, USA
    Clin Pharmacol Ther 82:572-8. 2007
  2. ncbi request reprint Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059
    Donald I Abrams
    San Francisco General Hospital, University of California at San Francisco, San Francisco, California 94110, USA
    J Acquir Immune Defic Syndr 29:221-31. 2002
  3. ncbi request reprint Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial
    D I Abrams
    Community Consortium, Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    Neurology 68:515-21. 2007
  4. ncbi request reprint Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study
    Donald I Abrams
    Community Consortium, Positive Health Program, University of California, San Francisco, CA 94143, USA
    AIDS Res Hum Retroviruses 23:77-85. 2007
  5. ncbi request reprint Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life
    D I Abrams
    UCSF Positive Health Program, San Francisco General Hospital, California 94110, USA
    Int J STD AIDS 11:659-65. 2000
  6. doi request reprint Cannabinoid-opioid interaction in chronic pain
    D I Abrams
    Division of Hematology Oncology, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 90:844-51. 2011
  7. ncbi request reprint Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 17:1907-15. 2003
  8. ncbi request reprint Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
    K Mulligan
    Department of Medicine, University of California San Francisco, 94110, USA
    J Acquir Immune Defic Syndr 26:443-8. 2001
  9. ncbi request reprint Potential interventions for HIV/AIDS wasting: an overview
    D I Abrams
    Positive Health Program, San Francisco General Hospital, University of California, 94110, USA
    J Acquir Immune Defic Syndr 25:S74-80. 2000
  10. ncbi request reprint Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 43:169-78. 2006

Detail Information

Publications31

  1. ncbi request reprint Vaporization as a smokeless cannabis delivery system: a pilot study
    D I Abrams
    Community Consortium, Positive Health Program, San Francisco General Hospital, San Francisco, California, USA
    Clin Pharmacol Ther 82:572-8. 2007
    ..No adverse events occurred. Vaporization of cannabis is a safe and effective mode of delivery of THC. Further trials of clinical effectiveness of cannabis could utilize vaporization as a smokeless delivery system...
  2. ncbi request reprint Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059
    Donald I Abrams
    San Francisco General Hospital, University of California at San Francisco, San Francisco, California 94110, USA
    J Acquir Immune Defic Syndr 29:221-31. 2002
    ..0001). No unanticipated adverse experiences were seen in this trial, to our knowledge the largest randomized evaluation of rIL-2 treatment conducted to date...
  3. ncbi request reprint Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial
    D I Abrams
    Community Consortium, Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
    Neurology 68:515-21. 2007
    ..To determine the effect of smoked cannabis on the neuropathic pain of HIV-associated sensory neuropathy and an experimental pain model...
  4. ncbi request reprint Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: a randomized placebo-controlled study
    Donald I Abrams
    Community Consortium, Positive Health Program, University of California, San Francisco, CA 94143, USA
    AIDS Res Hum Retroviruses 23:77-85. 2007
    ....
  5. ncbi request reprint Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life
    D I Abrams
    UCSF Positive Health Program, San Francisco General Hospital, California 94110, USA
    Int J STD AIDS 11:659-65. 2000
    ..Adverse events observed during epoetin alfa therapy were consistent with HIV disease and not likely due to the drug. Epoetin alfa therapy should be considered a treatment option for HIV-infected patients with mild-to-moderate anaemia...
  6. doi request reprint Cannabinoid-opioid interaction in chronic pain
    D I Abrams
    Division of Hematology Oncology, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, USA
    Clin Pharmacol Ther 90:844-51. 2011
    ..We therefore concluded that vaporized cannabis augments the analgesic effects of opioids without significantly altering plasma opioid levels. The combination may allow for opioid treatment at lower doses with fewer side effects...
  7. ncbi request reprint Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, University of California, San Francisco, California, USA
    AIDS 17:1907-15. 2003
    ..To determine the extent to which HIV-infected patients, including those with advanced immunodeficiency, can reverse peripheral CD4 T-cell depletion while maintaining long-term viral suppression on highly active antiretroviral therapy...
  8. ncbi request reprint Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy
    K Mulligan
    Department of Medicine, University of California San Francisco, 94110, USA
    J Acquir Immune Defic Syndr 26:443-8. 2001
    ..Our results, which have been obtained retrospectively, are intended to provide the impetus for prospective, controlled studies of the interactions among drug and host factors in the development of fat distribution abnormalities...
  9. ncbi request reprint Potential interventions for HIV/AIDS wasting: an overview
    D I Abrams
    Positive Health Program, San Francisco General Hospital, University of California, 94110, USA
    J Acquir Immune Defic Syndr 25:S74-80. 2000
    ..HIV wasting therapies are reviewed. The evaluation of some of these treatments for management of body habitus alterations associated with antiretroviral therapies may be appropriate...
  10. ncbi request reprint Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    J Acquir Immune Defic Syndr 43:169-78. 2006
    ....
  11. ncbi request reprint Nausea at the end of adjuvant cancer treatment in relation to exercise during treatment in patients with breast cancer
    Jiyeon Lee
    School of Nursing, University of California, San Francisco, USA
    Oncol Nurs Forum 35:830-5. 2008
    ..To evaluate the relationship between nausea and exercise during and after adjuvant cancer treatment (chemotherapy and radiation therapy or chemotherapy alone)...
  12. ncbi request reprint Contrasts, conflicts, and change: A case in cultural oncology
    Anand Dhruva
    Hematology Oncology Division, San Francisco General Hospital, San Francisco, CA 94110, USA
    J Support Oncol 4:301-4. 2006
  13. ncbi request reprint Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial
    Donald I Abrams
    University of California, San Francisco, and Gladstone Institute of Virology and Immunology, San Francisco, California 94110, USA
    Ann Intern Med 139:258-66. 2003
    ..Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoid-protease inhibitor interactions (because both share cytochrome P-450 metabolic pathways)...
  14. ncbi request reprint Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
    Jody Lawrence
    Department of Medicine, Positive Health Program, San Francisco General Hospital, University of California, San Francisco, San Francisco, CA 94110, USA
    N Engl J Med 349:837-46. 2003
    ..We compared two strategies for treating patients infected with multidrug-resistant human immunodeficiency virus (HIV)...
  15. ncbi request reprint Serum beta 2-microglobulin decreases in patients with AIDS or ARC treated with azidothymidine
    M A Jacobson
    Department of Medicine, University of California, San Francisco
    J Infect Dis 159:1029-36. 1989
    ..05). Serum beta 2-microglobulin appears to be a sensitive marker for in vivo antiretroviral drug activity and may be a better marker than serum p24 antigen for early intervention trials involving antiretroviral agents...
  16. ncbi request reprint The pre-AIDS syndromes. Asymptomatic carriers, thrombocytopenic purpura, persistent generalized lymphadenopathy, and AIDS-related complex
    D I Abrams
    Department of Medicine, University of California, San Francisco
    Infect Dis Clin North Am 2:343-51. 1988
    ..All are characterized by the presence of human immunodeficiency virus infection, symptomatic illness, and a tendency to progress to a diagnosis of full-blown AIDS that appears to be ever increasing with the passage of time...
  17. ncbi request reprint Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex
    D I Abrams
    University of California, San Francisco
    Ann Intern Med 110:183-8. 1989
    ..No evidence of systemic absorption of the parent compound is available. However, in view of the promising in vitro effects and acceptable toxicity, oral dextran sulfate as a potential antiretroviral agent continues to be studied...
  18. ncbi request reprint A phase I/II study of recombinant tumor necrosis factor and recombinant interferon gamma in patients with AIDS-related complex
    L D Kaplan
    Department of Medicine, San Francisco General Hospital, California 94110
    Biotechnol Ther 1:229-36. 1989
    ..The mean CD4 cell number did not change significantly (176 +/- 143/mm3 pretherapy versus 279 +/- 305/mm3 posttherapy).(ABSTRACT TRUNCATED AT 250 WORDS)..
  19. ncbi request reprint Risk of cancers during interrupted antiretroviral therapy in the SMART study
    Michael J Silverberg
    Division of Research, Kaiser Permanente Northern California, Oakland, California 94110, USA
    AIDS 21:1957-63. 2007
    ..To compare rates of AIDS-defining and non-AIDS-defining malignancies between patients on a CD4 T-cell-guided antiretroviral therapy (ART) strategy and continuous ART...
  20. ncbi request reprint Clinical manifestations of HIV infection, including persistent generalized lymphadenopathy and AIDS-related complex
    D I Abrams
    Department of Medicine, University of California, San Francisco
    J Am Acad Dermatol 22:1217-22. 1990
    ..All are characterized by the presence of infection with HIV, symptomatic disease, and, over time, an increasing tendency to progress to "full-blown" AIDS...
  21. pmc Associations between water-treatment methods and diarrhoea in HIV-positive individuals
    J N S Eisenberg
    School of Public Health, University of California, Berkeley, CA 94720 7360, USA
    Epidemiol Infect 129:315-23. 2002
    ....
  22. ncbi request reprint The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir
    Bradley W Kosel
    Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94110, USA
    AIDS 16:543-50. 2002
    ..We present pharmacokinetic data from a randomized placebo-controlled study designed to evaluate the metabolic effects of smoked marijuana and dronabinol in HIV-infected patients receiving indinavir (IDV) or nelfinavir (NFV)...
  23. ncbi request reprint Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients
    Barry M Bredt
    Department of Medicine, General Clinical Research Center at San Francisco General Hospital, CA 94110, USA
    J Clin Pharmacol 42:82S-89S. 2002
    ..On the basis of these measurements and during this short 21-day study period, few statistically significant effects were noted on immune system phenotypes orfunctions in this patient population...
  24. ncbi request reprint Community-based clinical trials in hiv: the contributions of Mathilde Krim
    Donald I Abrams
    Community Consortium of Bay Area HIV Care Providers, Department of Hematology Oncology, San Francisco General Hospital, San Francisco, California, USA
    AIDS Patient Care STDS 20:480-5. 2006
  25. ncbi request reprint The efficacy of distant healing for human immunodeficiency virus--results of a randomized trial
    John A Astin
    California Pacific Medical Center, San Francisco, CA, USA
    Altern Ther Health Med 12:36-41. 2006
    ..The purpose of this study was to examine the potential efficacy of distant healing in a population of patients with human immunodeficiency virus (HIV)/aquired immune deficiency syndrome (AIDS)...
  26. ncbi request reprint The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT
    Sean Emery
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria Street, Sydney, NSW 2010, Australia
    Control Clin Trials 23:198-220. 2002
    ..This article describes the rationale supporting the trial in addition to reviewing the study design, coordination, and governance...
  27. ncbi request reprint Medicinal cannabis: rational guidelines for dosing
    Gregory T Carter
    Department of Rehabilitation Medicine, University of Washington School of Medicine, Seattle, WA 98531, USA
    IDrugs 7:464-70. 2004
    ..This paper will review the known chemistry and pharmacology of cannabis and, on that basis, discuss rational guidelines for dosing...
  28. pmc CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection
    Jason V Baker
    University of Minnesota, Minneapolis, USA
    AIDS 22:841-8. 2008
    ..Reductions in AIDS-related morbidity and mortality following the advent of combination antiretroviral therapy have coincided with relative increases in chronic non-AIDS end-organ diseases among HIV+ patients...
  29. pmc Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases
    Jason V Baker
    Department of Biostatistics, University of Minnesota, Minneapolis, MN, USA
    J Acquir Immune Defic Syndr 48:541-6. 2008
    ..Low CD4+ increases risk for both AIDS- and non-AIDS-related morbidity and mortality. The magnitude of CD4+ recovery early after initial antiretroviral therapy (ART) is important in the ultimate duration of immune depletion...
  30. pmc Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial
    William Burman
    Denver Public Health, 605 Bannock Street, Denver, CO 80204, USA
    J Acquir Immune Defic Syndr 49:142-50. 2008
    ..To compare the HIV transmission risk among patients randomized to episodic versus continuous antiretroviral therapy...
  31. ncbi request reprint Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2
    Norman Markowitz
    Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Clin Infect Dis 37:e115-20. 2003
    ..Baseline CD4+ cell count had no significant effect. The strong association between nadir CD4+ cell count and CD4+ cell count response suggests that immunologic losses resulting from HIV-mediated CD4+ cell depletion may be irreversible...